Compare NGL & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGL | OCUL |
|---|---|---|
| Founded | 1940 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2011 | 2014 |
| Metric | NGL | OCUL |
|---|---|---|
| Price | $15.43 | $7.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $27.09 |
| AVG Volume (30 Days) | 149.9K | ★ 2.7M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,156,159,000.00 | $1,990,000.00 |
| Revenue This Year | $5.18 | $1.88 |
| Revenue Next Year | N/A | $93.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.48 |
| 52 Week Low | $5.88 | $6.23 |
| 52 Week High | $19.06 | $16.44 |
| Indicator | NGL | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 28.60 |
| Support Level | $14.26 | $6.23 |
| Resistance Level | $16.70 | $9.77 |
| Average True Range (ATR) | 0.55 | 0.58 |
| MACD | -0.23 | -0.34 |
| Stochastic Oscillator | 10.03 | 12.13 |
NGL Energy Partners LP is a USA-based firm that owns and operates a vertically integrated energy business. The company's operating segments include Crude Oil Logistics, Water Solutions, and Liquids Logistics. It operates crude oil Logistics, owns pipeline injection stations, and offers services for the treatment and disposal of wastewater generated from crude oil and natural gas production, as well as for the disposal of solids, such as tank bottoms and drilling fluids. The firm also supplies natural gas liquids to retailers, wholesalers, refiners, and petrochemical plants and sells propane and distillates.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.